Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of nOPV2 at Different Intervals in Infants
NCT05033561Phase 3Completed
- Sponsor
- Fighting Infectious Diseases in Emerging Countries
- Start
- Dec 2021
- Primary completion
- May 2022
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nOPV2 in poliomyelitis, sponsored by Fighting Infectious Diseases in Emerging Countries. Started Dec 2021; status: completed.
02
Drugs
nOPV2
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT05033561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033561.